HHS & Healthcare Contracts Intelligence — March 25, 2026

$256M outlayed to date with $284M unexercised options and non-competed extension potential to 2029 ensures multi-year pharma revenue.

Two 2019 awards totaling $530M obligated through 2027 signal ongoing biodefense priorities despite long execution lags.

Long periods to 2027-2029 with partial outlays ($256M/$422M Emergent; $77M/$108M Mount Sinai) expose to delays or cuts.

Firm fixed price (Emergent) risks contractor cost overruns; cost-no-fee (Mount Sinai) limits profit.

Unexercised options total $328M ($284M Emergent + $44M Mount Sinai) for VIGIV services and flu R&D.

Mount Sinai's 16 subawards ($13M) highlight R&D collaboration network in flu vaccines.

Non-competed $422M VIGIV award to foreign-owned Emergent plus competed flu R&D show diverse paths to multi-year funding.

Cost-no-fee structures and subawards in $108M flu contract prioritize innovation over profits.

{"entity"=>"Emergent BioSolutions", "reason"=>"$422M obligation with $284M options and $256M outlayed signals near-term catalysts.", "trigger"=>"Option exercises or 2027 extension award"}

{"entity"=>"Icahn School of Medicine at Mount Sinai", "reason"=>"$44M unexercised options and $13M subawards indicate R&D network potential.", "trigger"=>"Subaward expansions or flu vaccine milestones"}

{"entity"=>"HHS ASPR/NIAID vaccine pipeline", "reason"=>"Concentration in biologics (PSC 6505/AN12) amid $530M obligations.", "trigger"=>"New awards >$100M in biodefense"}